Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: August 2024

MissionIRNewsBreaks – SenesTech Inc.’s (NASDAQ: SNES) Evolve(TM) Offers Proactive Approach to Growing Rat Problem

Posted on August 22, 2024 by MissionIR

SenesTech’s (NASDAQ: SNES) flagship product, Evolve(TM), has repeatedly demonstrated an effective rat control alternative to current market offerings. “The active ingredient in the product has been scientifically proven to reduce rodent fertility, ultimately offering a more proactive approach to addressing … Continue reading →

Posted in SenesTech Inc. SNES | Leave a comment

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Posted on August 22, 2024 by MissionIR

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, announced positive results of two independently conducted Phase 2 clinical trials, RESCUE-ALS and HEALEY ALS Platform Trials, of CNM-Au8 … Continue reading →

Posted in Clene Inc. CLNN | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results Supporting Potential Utility of DehydraTECH-CBD in Diabetes Control

Posted on August 21, 2024 by MissionIR

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced receipt of blood glucose results from weeks 4 and 8 of its ongoing animal study WEIGHT-A24-1. The study is underway using diabetic, pre-conditioned Zucker rats. The … Continue reading →

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), EIB Close on Loan Restructuring Agreement

Posted on August 21, 2024 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has closed on its previously announced loan restructuring agreement. … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

D-Wave Quantum Inc. (NYSE: QBTS) Reports Strong Q2 2024 Results

Posted on August 21, 2024 by MissionIR

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the first commercial provider of quantum computers, released its second quarter 2024 financial results along with recent business and technical updates. The company reported growth in … Continue reading →

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

MissionIRNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS), NTT DOCOMO Report on Quantum Optimization Pilot Program Resulting in 15% Improved Mobile Network Performance

Posted on August 21, 2024 by MissionIR

D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, has partnered with NTT DOCOMO Inc., Japan’s largest mobile phone operator, to work on a quantum optimization … Continue reading →

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

MissionIRNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Quantum AI Product Roadmap Enhancements Highlighted in Syndicated Broadcast

Posted on August 20, 2024 by MissionIR

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, is featured in a NetworkNewsAudio (“NNA”) broadcast. NNA broadcasts are designed to provide additional visibility, recognition … Continue reading →

Posted in Small Cap News | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder

Posted on August 20, 2024 by MissionIR

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, has entered into a $2 million Investment Commitment Agreement with RK Stone Miami LLC, … Continue reading →

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

Posted on August 20, 2024 by MissionIR

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s Association International Conference(R) 2024 (AAIC(R)) … Continue reading →

Posted in Small Cap News | Leave a comment

MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Continues to Expand Presence in Higher Education Sector with New Vehicle Order

Posted on August 19, 2024 by MissionIR

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced the sale of the Mullen THREE, Class 3 EV box truck uplift to the facilities operations unit at Princeton University. The Mullen THREE is expected to support the … Continue reading →

Posted in Mullen Automotive Inc. MULN | Leave a comment